亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

Octopamine hcl

 
 
單價 面議對比
詢價 暫無
發貨 江西吉安市付款后3天內
品牌 SANPHARM
型號 770-05-8
規格 99%min
過期 長期有效
更新 2013-12-09 16:08
 

江西三豐精細化工有限公司

企業會員第15年
資料未認證
保證金未繳納
  • 江西-吉安市
  • 上次登錄 2013-12-09
  • 三豐化工 (先生)   銷售經理
詳細說明

Products List

1. Nutritional Ingredients 

No.  Product Name                 CAS No.     Specification

1.   Octopamine Hcl                 770-05-8     99.0%min

2.   Synephrine Hcl                 5985-28-4    99.0%min

3.   Beta-MethoxySynephrine Hcl     150961-17-0  99.0%min

Deeply honoured to supply the following products,thank you!

Sanpharm Co., Ltd.

Tel:+86-571-88983086  

Email:sanpharm@yeah.net 

MSN:sanpharma@hotmail.* 

QQ:565473514

舉報收藏 0評論 0
更多>本企業其它產品
Synephrine Hcl 布他磷;Butaphosphan;Butafosfan 伊馬替尼 中間體 Xanthoanthrafil (R)-Xanthoanthrafil 2-硝基咪唑 527-73-1 5-硝基-2-氟苯甲酸 7304-32-7
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |